Author's Reply to: "Comment on: Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials Including 31,397 Subjects Worldwide"...Konipineni S, Valecha J, Meme CD, et al. Am J Cardiovasc Drugs 26, 507–509 (2026).

This letter addresses the use of trial sequential analysis (TSA) in evaluating colchicine for secondary prevention of cardiovascular disease (CVD), responding to comments by Konipineni et al. The authors acknowledge TSA’s benefits but highlight its limitations, including sensitivity to assumptions a...

Descripción completa

Detalles Bibliográficos
Publicado en:	American Journal of Cardiovascular Drugs Vol. 26; no. 4; pp. 511 - 513
Autores principales:	Li, Hoi-Ying, Cheriyan, Joseph, Chan, Tsz-Kwan, Yiu, Kai-Hang, Tse, Hung-Fat, Wilkinson, Ian B., Chan, Yap-Hang
Formato:	letter response Journal Article
Publicado:	Springer Nature Jul2026
Acceso en línea:	Ver este registro en EBSCOhost

Descripción
Sumario:	This letter addresses the use of trial sequential analysis (TSA) in evaluating colchicine for secondary prevention of cardiovascular disease (CVD), responding to comments by Konipineni et al. The authors acknowledge TSA’s benefits but highlight its limitations, including sensitivity to assumptions and recommendations against its use for updated meta-analyses by the Cochrane Scientific Committee. They note that TSA results generally support colchicine’s protective effect in CVD, particularly at cumulative exposures ≥90 mg-days, and emphasize that findings from the COLCOT trial reinforce colchicine’s benefit in acute atherothrombotic CVD. The letter underscores the importance of integrating statistical methods with clinical context when interpreting evidence in cardiovascular medicine.